1.
Br J Surg
; 108(3): 239-243, 2021 04 05.
Article
in English
| MEDLINE
| ID: mdl-33793718
Subject(s)
Biomarkers, Tumor/genetics , Carcinoma, Pancreatic Ductal/genetics , Circulating Tumor DNA/blood , Neoplasm Recurrence, Local/diagnosis , Pancreatic Neoplasms/genetics , Proto-Oncogene Proteins p21(ras)/genetics , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Carcinoma, Pancreatic Ductal/blood , Carcinoma, Pancreatic Ductal/mortality , Carcinoma, Pancreatic Ductal/surgery , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/blood , Neoplasm Recurrence, Local/genetics , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/surgery , Prospective Studies , Proto-Oncogene Proteins p21(ras)/blood
2.
Infusionstherapie
; 18(6): 306-9, 1991 Dec.
Article
in German
| MEDLINE
| ID: mdl-1724661
ABSTRACT
In an open and uncontrolled trial the frequency and the type of adverse events were registered in patients who received Haemofusin, a hydroxyethyl starch solution, either for volume substitution or haemodilution. A total of 379 patients were investigated. No serious allergic reaction occurred. Headache, fever, rigor, light allergic reactions and nausea were documented in 17 patients. Even if one assumes that these observed concomitant events were caused by the hydroxyethyl starch, Haemofusin proved to be a well-tolerated colloid with a low rate of side effects (4.5%).